Dendritic cell vaccine - Tella

Drug Profile

Dendritic cell vaccine - Tella

Alternative Names: Regulatory dendritic cell vaccine therapy - Tella; Tumour peptide-pulsed dendritic cell vaccine - Tella; Vaccell - Tella

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Tella
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Biliary cancer; Malignant melanoma; Pancreatic cancer
  • Phase I Liver cancer; Oesophageal cancer
  • Research Allergic rhinitis; Autoimmune disorders

Most Recent Events

  • 22 Feb 2016 Tumour peptide pulsed dendritic cell vaccine is still in phase I/II trials for Pancreatic cancer, Biliary cancer and Malignant melanoma in Japan
  • 03 Apr 2015 Interim efficacy and adverse events data from a phase I trial in Pancreatic cancer released by Tella
  • 05 Oct 2013 Phase-I clinical trials in Liver cancer (GPC3/AFP/MAGE1 peptide-pulsed dendritic cell vaccine, second-line therapy or greater) in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top